NRX Pharmaceuticals (NRXP) Income towards Parent Company (2017 - 2026)

NRX Pharmaceuticals (NRXP) has 10 years of Income towards Parent Company data on file, last reported at -$5.0 million in Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 29.33% year-over-year to -$5.0 million in Q1 2026; TTM through Mar 2026 was -$17.5 million, a 7.32% decrease from a year earlier, with the FY2025 full-year figure at -$67.4 million, up 1.04% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$5.0 million, down from -$4.6 million in the prior quarter.
• Over the last five years, Income towards Parent Company for NRXP reached as high as -$2.4 million in Q4 2024 and fell as low as -$16.7 million in Q1 2022.
• Historically, Income towards Parent Company has averaged -$6.5 million across 5 years, with a median of -$5.0 million in 2026.
• Across the five-year window, Income towards Parent Company tumbled 1769.83% in 2022 and soared 76.26% in 2023, its largest moves.
• Year by year, Income towards Parent Company stood at -$12.3 million in 2022, then jumped by 64.15% to -$4.4 million in 2023, then jumped by 44.97% to -$2.4 million in 2024, then sank by 90.28% to -$4.6 million in 2025, then fell by 7.58% to -$5.0 million in 2026.
• Per Business Quant data, the three most recent Income towards Parent Company figures were -$5.0 million in Q1 2026, -$4.6 million in Q4 2025, and -$4.2 million in Q3 2025.